[EN] NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE TROUBLES DU SNC
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2011018495A1
公开(公告)日:2011-02-17
The invention relates to novel pyrazolopyrimidinones according to formula (I). The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.
The invention relates to novel pyrazolopyrimidinones according to formula (I).
The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.
Enantiotopic-Place Selective C-H Oxidation Using a (Salen)manganese(III) Complex as a Catalyst
作者:Akio Miyafuji、Tsutomu Katsuki
DOI:10.1055/s-1997-5780
日期:1997.7
A highly enantiotopic-place selective C-H oxidation of cyclic ether (up to 82% ee) was first achieved by using (R,R)-(salen)manganese(III) complex 8 as a catalyst.
[reaction: see text] An efficient oxidative lactonization of 1,4-diols in acetone is accomplished by the well-defined ruthenium catalyst, whose bifunctional nature underlies the high efficiency as well as unique chemo- and regioselectivity of the reaction which provides a rapid access to gamma-butyrolactones including flavor lactones hinokinin, and muricatacin.